Literature DB >> 27722869

Plague Vaccines: Status and Future.

Wei Sun1.   

Abstract

Three major plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people in human history. Due to its extreme virulence and the ease of its transmission, Y. pestis has been used purposefully for biowarfare in the past. Currently, plague epidemics are still breaking out sporadically in most of parts of the world, including the United States. Approximately 2000 cases of plague are reported each year to the World Health Organization. However, the potential use of the bacteria in modern times as an agent of bioterrorism and the emergence of a Y. pestis strain resistant to eight antibiotics bring out severe public health concerns. Therefore, prophylactic vaccination against this disease holds the brightest prospect for its long-term prevention. Here, we summarize the progress of the current vaccine development for counteracting plague.

Entities:  

Keywords:  Plague; Vaccines; Yersinia pestis

Mesh:

Substances:

Year:  2016        PMID: 27722869      PMCID: PMC6559729          DOI: 10.1007/978-94-024-0890-4_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  280 in total

1.  Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation.

Authors:  A Poltorak; P Ricciardi-Castagnoli; S Citterio; B Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

2.  Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague.

Authors:  S E Leary; K F Griffin; E E Galyov; J Hewer; E D Williamson; A Holmström; A Forsberg; R W Titball
Journal:  Microb Pathog       Date:  1999-03       Impact factor: 3.738

3.  Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus.

Authors:  A M Bennett; R J Phillpotts; S D Perkins; S C Jacobs; E D Williamson
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

4.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

5.  An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.

Authors:  E D Williamson; P M Vesey; K J Gillhespy; S M Eley; M Green; R W Titball
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis.

Authors:  M Achtman; K Zurth; G Morelli; G Torrea; A Guiyoule; E Carniel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

7.  Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice.

Authors:  G E Benner; G P Andrews; W R Byrne; S D Strachan; A K Sample; D G Heath; A M Friedlander
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.

Authors:  B P Arulanandam; M O'Toole; D W Metzger
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

9.  Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis.

Authors:  G P Andrews; S T Strachan; G E Benner; A K Sample; G W Anderson; J J Adamovicz; S L Welkos; J K Pullen; A M Friedlander
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

10.  Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers.

Authors:  M D DiPetrillo; T Tibbetts; H Kleanthous; K P Killeen; E L Hohmann
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

View more
  4 in total

Review 1.  Plague vaccine: recent progress and prospects.

Authors:  Wei Sun; Amit K Singh
Journal:  NPJ Vaccines       Date:  2019-02-18       Impact factor: 9.399

Review 2.  Plague vaccines: new developments in an ongoing search.

Authors:  Jason A Rosenzweig; Emily K Hendrix; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-18       Impact factor: 4.813

Review 3.  Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.

Authors:  Manfred S Green; James LeDuc; Daniel Cohen; David R Franz
Journal:  Lancet Infect Dis       Date:  2018-10-16       Impact factor: 25.071

4.  Peptidoglycan-Free Bacterial Ghosts Confer Enhanced Protection against Yersinia pestis Infection.

Authors:  Svetlana V Dentovskaya; Anastasia S Vagaiskaya; Mikhail E Platonov; Alexandra S Trunyakova; Sergei A Kotov; Ekaterina A Krasil'nikova; Galina M Titareva; Elizaveta M Mazurina; Tat'yana V Gapel'chenkova; Rima Z Shaikhutdinova; Sergei A Ivanov; Tat'yana I Kombarova; Vladimir N Gerasimov; Vladimir N Uversky; Andrey P Anisimov
Journal:  Vaccines (Basel)       Date:  2021-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.